1. Polycystic ovary syndrome: What is it? Pathogenetic enigma and therapeutic dilemma

   • V. Toscano

   Introduction 11 April 2014 Pages: 546 - 550

2. Polycystic ovary syndrome — loss of the apoptotic mechanism in the ovarian follicles?

   • Roy Homburg
   • A. Amsterdam

   Views on Pathogenetic Mechanisms 11 April 2014 Pages: 552 - 557

3. Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: From a complex constellation to a simple sequence of prenatal onset

   • Lourdes Ibáñez
   • F. de Zegher
   • N. Potau

   Views on Pathogenetic Mechanisms 11 April 2014 Pages: 558 - 566

4. The pathogenesis of polycystic ovary syndrome: Lessons from ovarian stimulation studies

   • Randall B. Barnes

   Views on Pathogenetic Mechanisms 11 April 2014 Pages: 567 - 579

5. Adrenal hyperandrogenism in the pathophysiology of polycystic ovary syndrome

   • Enrico Carmina
   • R. A. Lobo

   Views on Pathogenetic Mechanisms 11 April 2014 Pages: 580 - 588

6. Polycystic ovary syndrome and insulin resistance: Thrifty genes struggling with over-feeding and sedentary life style?

   • Jan Holte

   Views on Pathogenetic Mechanisms 11 April 2014 Pages: 589 - 601

7. Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome

   • Janet E. Hall
   • A. E. Taylor
   • W. F. Crowley Jr.

   Views on Pathogenetic Mechanisms 11 April 2014 Pages: 602 - 611

8. How possible is the prevention of polycystic ovary syndrome development in adolescent patients with early onset of hyperandrogenism

   • Dan Apter

   Opinions on Therapeutic Aspects 11 April 2014 Pages: 613 - 617

9. Estrogen — Progestagen therapy in the management of the polycystic ovary syndrome

   • John C. Marshall

   Opinions on Therapeutic Aspects 11 April 2014 Pages: 618 - 622

10. How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

    • Evanthia Diamanti-Kandarakis

    Opinions on Therapeutic Aspects 11 April 2014 Pages: 623 - 629

11. The feasibility of long-term treatment of polycystic ovary syndrome with GnRH-agonists

    • Sarah L. Berga

    Opinions on Therapeutic Aspects 11 April 2014 Pages: 630 - 631

12. Attenuation of hyperinsulinemia in polycystic ovary syndrome: What are the options?

    • David A. Ehrmann

    Opinions on Therapeutic Aspects 11 April 2014 Pages: 632 - 635

13. How actual is the dietary treatment in overweighting patients with polycystic ovary syndrome?

    • C. Cortet-Rudelli
    • Didier Dewailly

    Opinions on Therapeutic Aspects 11 April 2014 Pages: 636 - 640

14. Highlights 1995–1998

    • Roberto Castello

    Announcement 11 April 2014 Pages: 641 - 647

15. New routes in the polycystic ovary syndrome labyrinth: A way out?

    • Paolo Moghetti
    • R. Castello

    Conclusion 11 April 2014 Pages: 648 - 655